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CASE REPORT
Severe Secondary Polycythemia in a Female-to-Male Transgender
Patient While Using Lifelong Hormonal Therapy: A Patient’s
Perspective
Ellen G. T. Ederveen1 • Florence P. A. M. van Hunsel1 • Marielle J. Wondergem2 •
Euge`ne P. van Puijenbroek1,3
 The Author(s) 2018. This article is an open access publication
Abstract After a registered drug is available on the market
and used in everyday circumstances, hitherto unknown
adverse drug reactions (ADRs) may occur. Furthermore,
the patient can experience a previously unknown course of
a known ADR. Voluntary reports by patients play an
important role in gaining knowledge about ADRs in daily
practice. The Netherlands Pharmacovigilance Centre Lareb
received a report from a 55-year-old female-to-male
transgender patient who experiences secondary poly-
cythemia while using lifelong testosterone therapy. The
onset age of the symptoms was 38 years. The symptoms
appeared gradually and after approximately 1 year it was
clear that the patient’s hemoglobin and hematocrit had
started to increase. A Naranjo assessment score of 6 was
obtained, indicating a probable relationship between the
patient’s polycythemia and use of the suspect drug. Poly-
cythemia is a known ADR in testosterone treatment, but
little attention has been paid to the possible severity and
complications of these symptoms as well as the impact on
the patient’s well-being.
Key Points
Patients play an important role in voluntary adverse
drug reaction (ADR) reporting systems in gaining
knowledge about ADRs in daily practice.
Transgender patients need lifelong hormonal
therapy, which can lead to ADRs with a large impact
on the their quality of life.
Polycythemia is a common adverse drug reaction
during testosterone treatment, which can lead to
severe complications.
Background
Pharmacovigilance is defined by the World Health Orga-
nization (WHO) as ‘‘the science and activities relating to
the detection, assessment, understanding and prevention of
adverse effects or any other drug-related problem’’ [1].
Voluntary reporting systems play an important role in
gaining knowledge about a drug’s safety in real-world
conditions. Voluntary reports can be seen as (clinical)
concerns about a drug and the suspected reaction [2]. Next
to healthcare professionals, patients play an important role
in reporting adverse drug reactions (ADRs) [3]. Patients
have various motives for reporting that can often be char-
acterized as altruistic or personal [4]. Usually, there are
multiple reasons for reporting. In The Netherlands, main-
tenance of the voluntary reporting system is carried out by
the Pharmacovigilance Centre Lareb. Recently, Lareb
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received a report concerning the development of secondary
polycythemia while using testosterone therapy in a female-
to-male (FTM) transgender patient. The patient with this
ADR had an altruistic motivation for reporting it: trans-
gender people use lifelong hormonal therapy, and therefore
ADRs may have a strong impact on patients’ well-being,
and the patient wished to raise awareness of this. In this
case report we describe, from a patient’s perspective, one
consequence of this lifelong hormonal therapy and the
importance of patient reports.
Case Presentation
In April 2016, the Netherlands Pharmacovigilance Centre
Lareb received a report of a 55-year-old FTM transgender
patient who developed secondary polycythemia. He
explained that 18 years ago he started with testosterone
injections of 250 mg once every 2 weeks. As desired, this
resulted in cessation of menstruation, voice deepening,
increase of muscle volume, and hair growth according to
the male pattern. After a year, the dosage was reduced to
250 mg once every 3 weeks, but unfortunately this dosage
appeared to be insufficient. Over the years, he used various
testosterone preparations (e.g., testosterone gel, testos-
terone injections of 100 mg weekly and injections of
1000 mg once every 12 weeks).
Approximately a year after start of the testosterone
therapy, the patient’s hemoglobin and hematocrit values
started to increase. A few years later, his hemoglobin value
slightly exceeded 11 mmol/L (reference range
8.5–11.0 mmol/L). Another 4 years later, his hemoglobin
value was 11.5 mmol/L and hematocrit was 53% (refer-
ence range 40–50%). Besides the elevated hemoglobin and
hematocrit, the erythrocytes were microcytic and had an
abnormal morphology. The Janus kinase 2 (JAK2) muta-
tion was negative (both exon 12 and 14), and therefore his
hematologist considered primary polycythemia (poly-
cythemia vera) to be highly unlikely.
Approximately 13 years after the start of hormonal
therapy, the patient started treatment with an anticoagulant,
acetylsalicylic acid in a dosage of 80 mg daily, and phle-
botomy for the polycythemia. The patient’s hemoglobin
value at that point was 11.7 mmol/L and the hematocrit
value was 53%. However, this therapy caused a decreased
iron count, fatigue, and sensitivity to developing furuncles.
Regarding the latter, iron is essential for normal function-
ing of the immune system—the susceptibility to infection
is increased by iron deficiency [5, 6].
Approximately 5 months after initiation of the antico-
agulant and phlebotomy, the patient’s hemoglobin value
decreased to 8.1 mmol/L and the hematocrit value
decreased to 43%. The patient continued the testosterone
therapy, anticoagulant, and phlebotomy. Except for a few
abnormal values, the hemoglobin and hematocrit values
have been within the normal range since then. The patient
is now in an acceptable equilibrium with less frequent
phlebotomy treatments and he uses a small amount of iron
supplementation if his iron becomes too low for his well-
being.
The patient reported this ADR at the Netherlands
Pharmacovigilance Centre Lareb to raise awareness of the
possible severity and impact of this ADR. The causality of
the report was determined with a Naranjo assessment.
Since polycythemia is a known adverse event, other pos-
sible causes were excluded, and the symptoms appeared
after start of the testosterone, a Naranjo score of 6 was
obtained. This Naranjo score indicates a probable rela-
tionship between the patient’s polycythemia and the use of
testosterone.
Polycythemia is a known common ADR of testosterone
therapy but is usually mild in nature [7, 8]. It is important
that patients who are planning to start hormonal therapy are
aware of this possible ADR.
Discussion
In the case report presented here, the patient used several
formulations of testosterone over time. Unfortunately,
since the patient changed hematologist, details about which
formulation corresponds to what blood values are lacking.
In addition, since the patient started the anticoagulant and
phlebotomy around the same time, it was unknown which
treatment contributed the most to the decreased hemoglo-
bin and hematocrit values. This also applies to the reduced
iron count, fatigue, and sensitivity to furuncles, which
appeared after the start of both the anticoagulant and
phlebotomy.
‘Transgender’ is an umbrella term to describe individ-
uals who differ from the cultural norm in gender expression
or gender role behavior [9]. Exact numbers of patients
diagnosed with gender dysphoria are lacking. The esti-
mated numbers are dependent on the terminology used and
the population studied, and vary broadly. However, avail-
able studies show that the number of patients presenting to
clinics is increasing but that the number that undergo an
actual transition to the opposite sex is considerably smaller
[9].
The aim of the transition is to change the mental and
physical state to that of the opposite sex. In addition to
psychotherapy and sex reassignment surgery, the treatment
consists of hormone replacement therapy [10]. For FTM
transgender patients this requires lifelong testosterone
administration. This therapy aims to induce the desired
virilization and cessation of menstruation.
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However, testosterone use can also lead to ADRs such
as acne, increased aggressiveness, and weight gain. The
label of testosterone injections mentions increased hemat-
ocrit, hemoglobin, and red blood cells and polycythemia as
a common ADR [11]. In secondary polycythemia, plasma
circulating factors such as erythropoietin or testosterone
stimulate erythropoiesis [12, 13]. Polycythemia may occur
in more than 20% of men receiving testosterone hormonal
replacement therapy. An increase in hemoglobin of 5–7%
during testosterone treatment has been described [13]. As
of 4 July 2017, VigiBase, the WHO international database
of suspected ADRs, had 14 reports of polycythemia vera
versus 218 of polycythemia related to testosterone treat-
ment [14].
The most common long-term complications of primary
polycythemia are thrombosis and malignancies [13, 15].
There is no conclusive evidence that secondary poly-
cythemia caused by testosterone replacement therapy is
associated with the same risks [16], although high blood
viscosity might increase the risk of thrombotic events
[16, 17]. It is unclear above what hematocrit level this risk
appears [17]. Furthermore, there is no conclusive evidence
that testosterone can be thrombogenic, with or without
causing erythrocytosis. It seems that starting testosterone
treatment, as investigated in men with age-related hypog-
onadism, increases the risk of thrombosis slightly, and that
this risk declines after the first 6 months [18].
Conclusion
To minimize the risk of polycythemia-induced complica-
tions, patients are often treated in the same manner as for
primary polycythemia, with phlebotomy and an antiplatelet
drug [15]. The best approach to treating the symptoms
would be to withdraw the hormonal therapy [19]; however,
withdrawal of testosterone therapy is not an option for most
FTM transgender patients. Before the start of hormonal
therapy it is important that patients are well-informed about
the possible ADRs, including polycythemia, since it may
have a large impact on their quality of life. Furthermore, a
blood count prior to the start of the therapy and monitoring
the complete blood count during long-term hormonal
therapy are essential [11]. In order to gain more knowledge
and to raise awareness about this ADR, it is important that
patients and healthcare professionals who treat transgender
patients report possible ADRs to their national pharma-
covigilance centers. To conclude, we add a quote that
shows the patient’s perspective on this ADR:
‘‘I believe that it is almost impossible to have a func-
tioning drug without this having an effect on other parts of
the body. If I would have known this adverse drug reaction
before start of the therapy, I would still choose to start this
therapy. Solely I would be more regardful of changes in my
blood values.’’
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